Protease-activated receptor-1 is the predominant receptor for thrombin on human platelets. Vorapaxar is a potent antagonist of protease-activated receptor-1 that inhibits thrombinmediated platelet activation. 4 Phase 2 trials of vorapaxar suggested efficacy with acceptable safety in patients with acute ischemic stroke. 4, 5 We previously reported the efficacy and safety of vorapaxar among a broad group of patients with prior atherothrombosis who enrolled in the Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Background and Purpose-Vorapaxar is an antiplatelet agent that antagonizes thrombin-mediated activation of the proteaseactivated receptor-1 on platelets. We tested the efficacy and safety of vorapaxar in a prespecified analysis in the stroke subcohort from a multinational, randomized, placebo-controlled trial. Methods-We randomly assigned patients with prior atherothrombosis (myocardial infarction, peripheral artery disease, or ischemic stroke) to receive vorapaxar (2.5 mg daily) or placebo added to standard antiplatelet therapy. Patients who qualified with stroke (N=4883) had a history of ischemic stroke in the prior 2 weeks to 12 months. The primary end point was the composite of cardiovascular death, myocardial infarction, or any stroke. Results-The qualifying stroke was classified as large vessel in 35%, small vessel in 47%, and other/unknown in 18%. In the stroke cohort, cardiovascular death, myocardial infarction, or stroke through 3 years was not reduced with vorapaxar versus placebo (13.0% vs 11.7%; hazard ratio, 1.03; 95% confidence interval, 0.85-1.25), including recurrent ischemic stroke (hazard ratio, 0.99; 95% confidence interval, 0.78-1.25). There were no significant differences in the effect of vorapaxar based on the type or timing of the qualifying stroke. Intracranial hemorrhage at 3 years was increased with vorapaxar (2.5% vs 1.0%; hazard ratio, 2.52; 95% confidence interval, 1.46-4.36). 
I
n the United States, nearly 800 000 strokes occur each year, with almost 1 in 4 being recurrent events. 1 Noncardioembolic ischemic strokes account for the majority of strokes and are an important target for secondary prevention. Because most noncardioembolic ischemic strokes are believed to occur as the result of atherothrombosis, antiplatelet agents are central to secondary prevention. 1 Patients with ischemic stroke are also at significant risk of atherothrombotic events in the coronary and peripheral arterial beds. 2 Efforts to improve antiplatelet strategies for secondary prevention after ischemic stroke have revealed a challenging balance between antithrombotic efficacy and bleeding. 1 Because patients with ischemic stroke treated with contemporary antiplatelet therapy are at high risk for both recurrent ischemic and hemorrhagic events, 2, 3 there is a need for agents that are both more efficacious and safer.
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Ischemic Events-Thrombolysis in Myocardial Infarction (TRA 2°P-TIMI 50) trial. 6 In the overall cohort of 26 449 patients with a history of myocardial infarction (MI), ischemic stroke, or peripheral arterial disease (PAD), vorapaxar reduced the risk of cardiovascular (CV) death, MI, or stroke by 13% (P<0.001) while increasing the risk of moderate or severe bleeding (P<0.001). It should be noted that in patients who qualified for the trial with MI, vorapaxar lowered CV death, MI, or stroke by a significant 20%. 7 In this prespecified analysis, we examined the efficacy and safety of vorapaxar, added to standard therapy, for secondary prevention in the 4883 patients who qualified for TRA 2°P-TIMI 50 with a prior ischemic stroke. We also evaluated the outcomes with vorapaxar in patients who qualified for the trial with MI or PAD but who also had a history of cerebrovascular disease.
Methods
Study Population
TRA 2°P-TIMI 50 was a multinational, double-blind, randomized, placebo-controlled trial. The design and primary results have been published. 6, 8 Between September 2007 and November 2009, 26 449 patients with prior atherothrombosis (MI, PAD, or ischemic stroke) were randomized. Patients who qualified for the trial on the basis of ischemic stroke were to have been hospitalized or evaluated in an acute stroke clinic with a final diagnosis of an ischemic (presumed thrombotic, noncardioembolic) stroke within 2 weeks to 12 months before randomization. By design, enrollment in the qualifying stroke group was completed after reaching ≈15% of the planned overall trial population. Patients were excluded if they had history at any time of intracranial hemorrhage, intracranial or spinal cord surgery, a central nervous system tumor or aneurysm, recent active abnormal bleeding, ongoing treatment with warfarin, or active hepatobiliary disease. Details of the full eligibility criteria have been reported. 8 The protocol was approved by the relevant ethics committee at all participating centers. Written informed consent was obtained from all patients.
Study Protocol
Eligible patients were randomly assigned in a 1:1 ratio to receive either vorapaxar (2.5 mg daily) or placebo by a central computerized system, stratified according to the qualifying atherothrombotic disease (MI, ischemic stroke, or PAD), and whether or not the responsible physician intended to administer a thienopyridine. All concomitant medical therapy, including the use of other antiplatelet agents, was managed by the treating clinicians according to local standards of care. As described previously, 6 after a median of 2 years of followup, the Data and Safety Monitoring Board reported an increased risk of intracranial hemorrhage with vorapaxar in participants with prior stroke and recommended that study drug be discontinued in all patients with a history of stroke before or during the trial. Patients who qualified for the trial with a prior ischemic stroke completed their participation with a final study visit at that time. Patients who qualified for the trial with an MI or PAD and discontinued study treatment because of a history of stroke continued follow-up until completion of the trial in the overall MI and PAD groups.
End Points
The data analysis plan 6 defined the primary efficacy analysis to begin with the composite of CV death, MI, or stroke, followed by CV death, MI, stroke, or urgent coronary revascularization, and then CV death or MI. The definitions for each component of the efficacy composite end points have been published. 8 The end point of stroke was defined as an acute focal neurological deficit of sudden onset consistent with vascular cause that was not reversible in <24 hours or that was accompanied by clear evidence of a new stroke on neuroimaging. 8 Bleeding was assessed using the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) and TIMI classification systems with GUSTO moderate or severe bleeding defined as the primary safety end point. 8 The subset of GUSTO severe bleeds that were intracranial hemorrhages was also reviewed and captured individually. All elements of the composite efficacy end points, and bleeding were adjudicated by a Clinical Events Committee blinded to treatment allocation.
Statistical Considerations
Analysis of the qualifying ischemic stroke cohort was prespecified in the analysis plan. 8 All analyses comparing vorapaxar versus placebo for efficacy were conducted on an intent-to-treat basis with a Cox proportional hazards model using only the covariates of treatment and intent to use a thienopyridine. Event rates are presented as Kaplan-Meier failure rates at 3 years. Additional subgroups were analyzed using a Cox proportional hazards model for terms of treatment, stratification factors, subgroup, and treatment-subgroup interaction. These analyses are inherently exploratory. Analyses were performed by the TIMI Study Group, who take responsibility for and decided to submit the article.
Results
Study Participants
In total, 4883 patients qualified for the trial on the basis of a prior ischemic stroke and were randomized to vorapaxar or placebo. Their baseline characteristics are presented in Table 1 . The qualifying ischemic stroke occurred 2 weeks to <3 months before randomization in 52% of patients, 3 to 6 months in 30%, and 6 to 12 months in 18%. Classification of the ischemic stroke type by the investigator is available for 4815 patients and indicates the qualifying stroke to be large vessel in 35%, small vessel (lacunar) in 47%, and other or unknown in the remainder.
Background medical therapy is shown in Table 1 . The majority of patients (54%) were treated with aspirin alone, 19% with aspirin plus dipyridamole, 16% with a thienopyridine alone, 7% with aspirin and a thienopyridine, and 0.6% with dipyridamole alone. This background therapy remained quite stable over the duration of the study with >85% of patients treated with the same background antiplatelet therapy at 1 year. Lipidlowering medications were administered to 78% of patients. The median duration of follow-up was 24 months (25th, 75th percentiles: 21, 29). Compliance with randomized study therapy was excellent with >95% of subjects receiving study therapy achieving ≥80% adherence through 2 years.
Primary Efficacy and Safety Analyses
For patients who qualified with an ischemic stroke, the 3-year incidence of CV death, MI, or stroke was 13.0% in the vorapaxar group compared with 11.7% in the placebo group; hazard ratio (HR) 1.03 (95% confidence interval [CI], 0.85-1.25; P=0.75; Figure 1A ). The major additional efficacy end points and individual elements of the composite are shown in Table 2 and reveal no significant difference between vorapaxar and placebo in any of the efficacy end points examined. In particular, recurrent stroke alone was not reduced with vorapaxar (10 Figure 1B ). Intracranial hemorrhage, inclusive of intracerebral and subdural bleeding, was significantly increased with vorapaxar (2.5% vs 1.0%; HR, 2.52; 95% CI, 1.46-4.36; P<0.001; Table 2 ). Intracerebral bleeding was significantly increased by vorapaxar with a small number of subdural or epidural bleeding events ( Table 2 ). The increased risk of intracranial hemorrhage emerged early and persisted ( Figure 1C ). Fatal bleeding was numerically higher with vorapaxar compared with placebo (Table 2) .
Subgroups
Exploratory examination of clinically relevant subgroups based on the type of qualifying ischemic stroke or the timing of the stroke relative to randomization did not reveal any statistically significant differences in the effect of vorapaxar ( Figure 2A ). Considering background antiplatelet therapy, there was no group in which the benefit of vorapaxar was definitively apparent (Figure 2A ). However, outcomes with vorapaxar compared with placebo in stroke patients tended in a more favorable direction among those managed with aspirin alone or in the small group with no other antiplatelet therapy. In patients treated with background aspirin monotherapy, the rates of CV death, MI, or recurrent stroke with vorapaxar versus placebo were 9.8% versus 10.9% (HR, 0.82; 95% CI, 0.62-1.09; P interaction versus all other antiplatelet combinations, 0.035).
There was no definitive heterogeneity in the risk of GUSTO severe or moderate bleeding ( Figure 2B ) or in the risk of intracranial hemorrhage (P>0.05 for each) with vorapaxar versus placebo in relation to the timing or type of stroke, or background antiplatelet therapy. In patients treated with background aspirin monotherapy, the 3-year rates of GUSTO severe or moderate bleeding with vorapaxar compared with placebo were 4.0% versus 2.4% (HR, 1.70; 95% CI, 1.00-2.87; P interaction versus all other antiplatelet combinations, 0.53), and for intracranial hemorrhage were 2.5% vs 1.3% (HR, 1.63; 95% CI, 0.80-3.33; P interaction versus all other antiplatelet combinations, 0.098).
Patients With MI and PAD With a History of Cerebrovascular Disease
Among the 17 779 patients who qualified for the trial with MI, 585 also had a history of prior ischemic stroke, the majority (81%) of which was >6 months preceding randomization. Within this group of patients, we observed 46 major CV events (CV death, MI, or stroke) with vorapaxar compared with 63 with placebo (HR, 0.69; 95% CI, 0.47-1.00; P=0.052; Table 3 ) with no heterogeneity in the effect of vorapaxar between MI patients with or without a history of stroke (P interaction=0.45). The overall number of intracranial hemorrhages in those with MI and prior stroke was very small (n=3) with 2 occurring in the vorapaxar group (0.9% vs 0.6%; P=0.56).
Among the 3787 patients who qualified for the trial with PAD, 304 had a history of ischemic stroke (96% >6 months before randomization). Within this group of patients, the rate of CV death, MI, or stroke events with vorapaxar did not differ compared with placebo (HR, 1.01; 95% CI, 0.61-1.70; P=0.96; P interaction=0.73; Table 3 ). Five intracranial hemorrhages occurred in those with PAD and prior stroke, with a risk of intracranial hemorrhage that tended to be higher with vorapaxar (3.5% vs 0.7%; HR, 3.72; 95% CI, 0.41-33.3;
P=0.24).
Combining the cohorts that qualified for the trial with MI or PAD, the risk of intracranial hemorrhage with vorapaxar tended to be higher among those with a history of stroke (2.1% vs 0.6%; HR, 2.90; 95% CI, 0.58-14.4; P=0.19) with lower absolute rates among MI or PAD patients without a history of stroke (0.6% vs 0.4%; HR, 1.55; 1.00-2.41; P=0.049; P interaction=0.45). Moreover, among the 498 patients who qualified for the trial with MI or PAD, who had a history of transient ischemic attack in the absence of a known prior stroke, the risk of intracranial hemorrhage appeared to increase similarly with vorapaxar (1.9% vs 0.5%; HR, 3.86; 95% CI, 0.43-34.5; P=0.23; P interaction versus no TIA, 0.40). 
Discussion
In this randomized, placebo-controlled, multinational trial, among patients with prior noncardioembolic ischemic stroke, the addition of the protease-activated receptor-1 antagonist vorapaxar to standard therapy did not reduce the rate of major CV events but increased the risk of major bleeding, including intracerebral hemorrhage. Analyses of subgroups did not reveal any clear benefit of vorapaxar within clinically relevant groups defined by the type and timing of prior ischemic stroke, or background antiplatelet therapy. For patients who qualified for the trial with a history of MI who also had a history of ischemic stroke, vorapaxar provided benefit that was similar to benefit provided to MI patients without a prior stroke. However, the risk of intracranial hemorrhage with vorapaxar appears to be magnified in this group as it was in patients who qualified for the trial on the basis of prior stroke. In addition, a similar pattern of increased risk of intracranial hemorrhage was apparent in patients with a history of TIA in the absence of a prior known stroke. These data add to the accumulating evidence revealing important risks of combination antiplatelet therapy for long-term secondary prevention in patients with ischemic stroke or TIA.
Antiplatelet agents are a mainstay of secondary prevention in patients with prior noncardioembolic stroke. However, existing data from randomized trials are mixed and have left uncertainty regarding the optimal regimen of antiplatelet therapy. For example, more than a decade ago, the combination of low-dose aspirin and dipyridamole was found more effective than either agent alone. 9 Moreover, a meta-analysis of 12 randomized trials involving 3766 patients undergoing therapy for acute stroke or TIA supported a reduction in combined vascular events with dual therapy compared with monotherapy without a significant increase in bleeding. 10 It is important that this analysis was focused on the acute phase of stroke and included trials of aspirin plus dipyridamole versus aspirin or dipyridamole alone. In contrast, 3 of the more recent, and largest, randomized trials of combination antiplatelet therapy for secondary prevention after ischemic stroke have failed to show a benefit over monotherapy. 11 Regimens studied included clopidogrel plus aspirin versus clopidogrel alone, 11 clopidogrel plus aspirin versus aspirin alone, 12 and aspirin plus extended-release dipyridamole versus clopidogrel. 13 In each of these trials, antiplatelet monotherapy showed similar efficacy compared with dual therapy, and less systemic and cerebral bleeding. [11] [12] [13] In our study, we found that patients who qualified for the trial with ischemic stroke were at high risk of recurrent major vascular events, compared with patients who qualified with prior MI (11.7% vs 9.6% placebo rates). 6 This higher risk highlights the importance of seeking new effective therapies for secondary prevention in patients with ischemic stroke. However, the addition of the protease-activated receptor-1 
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antagonist vorapaxar to standard antiplatelet therapy did not improve their outcomes. Although there was a trend toward a reduction in major vascular events with vorapaxar in the subgroup of patients treated with aspirin alone as background therapy, this possible effect was not statistically significant and was accompanied by a higher risk of intracranial hemorrhage. By its design, our trial does not address the question of whether vorapaxar could be effective as an alternative therapy administered alone in comparison with guideline-based antiplatelet therapy, especially in patients who experience a stroke while receiving standard antiplatelet therapy. The patterns in our trial of possible benefit with vorapaxar in patients who were treated with aspirin only or no other antiplatelet agent are supportive of this hypothesis but would require prospective assessment.
Our study reinforces the potential risk of intracranial bleeding with combination antiplatelet therapy for patients with prior ischemic stroke. The pattern of an increased risk of intracranial hemorrhage with vorapaxar was consistent in all major subgroups with prior stroke, including those who qualified for the trial with MI or PAD but who also had a history of stroke. Combination antiplatelet therapy with aspirin and a thienopyridine has been shown to increase the risk of intracranial hemorrhage compared with monotherapy both in patients with ischemic stroke 11, 12 and in patients with acute coronary syndromes with a history of stroke or TIA. 14 In the latter study, a history of TIA was not examined separately from prior stroke.
14 However, our findings suggest an increased risk of intracranial hemorrhage in those with prior TIA, who may be difficult to distinguish clinically from those with stroke. Our findings also highlight the contrasting outcomes with more potent combination therapy in patients with cerebrovascular disease alone compared with patients with coronary atherothrombosis. Specifically, vorapaxar significantly reduces major vascular events in patients with MI, particularly in patients without prior stroke or TIA who are at low absolute bleeding risk, 7 but showed no benefit in patients with ischemic stroke on the background of contemporary antiplatelet therapy at the dose and duration administered in this study.
Conclusions
In patients with prior ischemic stroke receiving standard antiplatelet therapy, adding vorapaxar increased the risk of intracranial hemorrhage without a reduction in either the primary efficacy end point or ischemic stroke alone. These findings add to the accumulating evidence establishing important risks with combination antiplatelet therapy in patients with prior stroke.
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Supplemental Methods
Study Protocol
Study therapy was to be interrupted if a new indication required treatment with warfarin in conjunction with a thienopyridine.
Classification of Stroke
The type of ischemic stroke was classified by the local investigator using all available diagnostic information obtained as part of standard care and applying the previously established Trial of Org 10172 in Acute Stroke Treatment (TOAST) criteria. 1 These criteria distinguish 5 major categories of ischemic stroke: 1) Large-artery occlusion (extra-cerebral or intra-cerebral); 2) Small artery occlusion (lacunar stroke, generally <15 mm subcortical size); 3) Cardioembolic, usually in the setting of atrial fibrillation, valvular disease, ventricular mural thrombus; 4) Cryptogenic (undetermined cause); or 5) Stroke of other cause (e.g. carotid or vertebral dissection). For the purposes of analyses in this study, the last 2 categories were analyzed together as Other/Unknown.
Efficacy Endpoints
The initial protocol-defined primary efficacy endpoint was the composite of cardiovascular death MI, stroke, or recurrent ischemia leading to urgent coronary revascularization with a major secondary endpoint of cardiovascular death, MI, or stroke. Prior to database lock, while 2 investigators, subjects, and the Sponsor remained blinded to the investigational treatment, in view of new information regarding vorapaxar from external data, the Steering Committee amended the main data analysis plan to reorder the hierarchy of the primary efficacy analysis to begin with the composite of cardiovascular death, MI, or stroke, followed by cardiovascular death, MI, stroke, or urgent coronary revascularization, and then cardiovascular death or MI.
2
This reordering of the primary efficacy analysis was made in light of the diminishing clinical importance of urgent coronary revascularization (in the absence of myocardial necrosis meeting the definition of myocardial infarction) as an endpoint in the era of increased sensitivity of cardiac troponin, and the absence of an effect of vorapaxar on the 'softer' endpoints of recurrent ischemia leading to revascularization or myocardial ischemia leading to hospitalization in a completed trial of vorapaxar vs. placeob in patients with acute coronary syndromes. 3 Each endpoint, including any stroke, was reviewed by the Clinical Events Committee (CEC), blinded to treatment allocation, and using all available source documentation, inclusive of hospital notes, neurological consultant notes, discharge summaries, laboratory data, all relevant brain imaging, and autopsy data where applicable. All potential stroke endpoint events were separately reviewed according to the previously published trial definition 4 (below) by 2 neurologist members of the CEC, and a third reviewer entered as a tie-breaker if agreement was not achieved.
The endpoint of stroke was defined as an acute focal neurological deficit of sudden onset, a) that is not reversible within 24 hours or results in death (in <24 hours) and is not due to an identifiable non-vascular cause (ie, brain tumor, trauma), or b) that resolves in <24 hours and is accompanied by clear evidence of a new stroke on cerebral imaging
Statistical Analyses
The raw database was provided to and analyses were carried out independently by the TIMI Study Group, whose members had complete access to the data, prepared this report, take responsibility for the data, and had responsibility for the decision to submit the manuscript. Safety analyses were performed among patients who received one or more doses of study medication and included events through 60 days after premature cessation of study therapy or 30 days after a final visit.
2
Because all analyses presented were considered exploratory, the criteria for interpretation of pvalues were not corrected for multiple comparisons.
Supplemental Results
An on-treatment sensitivity analysis (censored at 3 days after permanent discontinuation of study drug) also showed no effect of vorapaxar on the endpoint of cardiovascular death, myocardial infarction or stroke, in the cohort with qualifying stroke (HR 1.06; 95% CI 0.87-1.32) indicating that there was no meaningful influence of premature permanent discontinuation on the effect estimate for vorapaxar in this population.
